Research
KPV in intestinal research
KPV in intestinal epithelial cells and rodent colitis models, the PepT1 transporter link, and nanoparticle and hydrogel delivery studies.
By the KPV Peptide editorial team · Last reviewed · Editorial review: approved by Ryan DeLauz (bulk sign-off in chat, 2026-11-11)
Short answer
Intestinal research is the largest part of the KPV literature: 9 indexed studies using human intestinal cell lines and chemically induced colitis in mice and rats. 6 of them test KPV inside a delivery system such as nanoparticles or hydrogels. None involves people[FDA briefing 2026].
The PepT1 link
PepT1 is a transporter for di- and tripeptides, normally found in the small intestine. A 2008 study reported that KPV enters intestinal epithelial and T cells through PepT1, lowered NF-κB and MAP-kinase activation at nanomolar concentrations, and reduced inflammation scores in DSS- and TNBS-induced mouse colitis when given in drinking water [Dalmasso 2008]. A 2016 study in PepT1-knockout mice supported the transporter’s role [Viennois 2016].
Receptor-independent effects
In DSS and T-cell-transfer colitis models, KPV-treated mice regained weight faster and had lower colonic myeloperoxidase, including mice lacking a functional MC1 receptor [Kannengiesser 2008].
Delivery systems
Most later work asks how to deliver KPV to the inflamed colon. Polymer nanoparticles in an alginate–chitosan gel produced similar effects at a much lower concentration than KPV solution [Laroui 2010]; hyaluronic-acid-targeted particles outperformed non-targeted ones [Xiao 2017]; and a 2026 ROS-responsive prodrug achieved 3.8-fold higher colonic accumulation than free KPV [Cheng 2026]. These results describe formulations, not KPV alone.
Studies in this area
| Study | Model | What was measured | Limitations | Grade |
|---|---|---|---|---|
| Dalmasso 2008 Gastroenterology Intestinal inflammation models | Animal Caco2-BBE, HT29-Cl.19A and Jurkat cells; DSS and TNBS colitis models in mice | Measured PepT1-mediated uptake, NF-kappaB and MAP kinase activation, and colonic cytokine mRNA; nanomolar KPV reduced these readouts and the two chemically induced colitis models showed lower inflammation scores. | Chemically induced mouse models; cytokine and histology endpoints only. | Evidence grade C |
| Kannengiesser 2008 Inflamm Bowel Dis Intestinal inflammation models | Animal DSS colitis and CD45RB(hi) transfer colitis in mice; MC1R e/e mice | Measured weight recovery, histological infiltrates and colonic myeloperoxidase; KPV-treated mice showed faster weight regain, fewer infiltrates and lower MPO, including MC1R-deficient mice. | Mouse models only; group sizes not in abstract. | Evidence grade C |
| Laroui 2010 Gastroenterology Intestinal inflammation models · Delivery and formulation | Animal Caco2-BBE cells; DSS colitis in mice | Measured epithelial inflammatory responses and colitis parameters; nanoparticle-delivered KPV gave similar effects at a concentration reported as 12,000-fold lower than free KPV solution. | Formulation effect, not free KPV; mouse model. | Evidence grade C |
| Viennois 2016 Cell Mol Gastroenterol Hepatol Intestinal inflammation models · Tumour-model research | Animal AOM/DSS colitis-associated tumour model in WT, hPepT1-transgenic and PepT1-KO mice; human colonic biopsies | Measured tumour number and size in a chemically induced colitis-associated tumour model; tumour burden tracked PepT1 expression, and KPV reduced tumorigenesis in wild-type but not PepT1-knockout mice. | Mouse model; the human biopsies measured PepT1 expression only, with no KPV exposure. | Evidence grade C |
| Xiao 2017 Mol Ther Intestinal inflammation models · Delivery and formulation | Animal Colonic epithelial cells and macrophages; mouse colitis model | Measured mucosal damage and TNF-alpha; the HA-functionalised nanoparticle/hydrogel system outperformed a non-targeted KPV nanoparticle system. | Formulation effect; mouse model. | Evidence grade C |
| Sun 2021 ACS Biomater Sci Eng Intestinal inflammation models · Delivery and formulation | Animal TNBS colitis in rats (rectal) | Measured release kinetics, stability at 37 C, weight loss, disease activity index, colon length, MPO, TNF-alpha and IL-6 in TNBS-treated rats given the hydrogel formulation. | Formulation effect; rat model. | Evidence grade C |
| Zhao 2022 Acta Biomater Intestinal inflammation models · Delivery and formulation | Animal TNBS colitis in rats (intracolonic) | Measured mucosal adhesion, epithelial barrier recovery and gut flora composition in TNBS-treated rats given the hydrogel-bound KPV. | Formulation effect; rat model. | Evidence grade C |
| Zhang 2024 Front Pharmacol Intestinal inflammation models · Delivery and formulation | Animal Acute and chronic DSS colitis in mice; macrophages | Measured body weight, colon length, disease activity index, MPO, NO, ROS, TNF-alpha, IL-1 beta, IL-6 and tight-junction proteins; the co-assembled nanoparticles exceeded both the KPV-only and FK506-only groups. | Combination with an immunosuppressant; free-KPV arm was a comparator, not the focus. | Evidence grade C |
| Cheng 2026 Sci Adv Intestinal inflammation models · Airway epithelium · Delivery and formulation | Animal Mouse colitis and acute lung injury models | Measured colonic accumulation and inflammatory endpoints; the conjugate reached 3.8-fold higher colonic accumulation than free KPV. | Prodrug conjugate, not free KPV. | Evidence grade C |
References
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HT et al. (2008). PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. PubMed 18061177 · doi:10.1053/j.gastro.2007.10.026[Animal, grade C]
- Kannengiesser K, Maaser C, Heidemann J et al. (2008). Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. PubMed 18092346 · doi:10.1002/ibd.20334[Animal, grade C]
- Viennois E, Ingersoll SA, Ayyadurai S et al. (2016). Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model. Cell Mol Gastroenterol Hepatol. PubMed 27458604 · doi:10.1016/j.jcmgh.2016.01.006[Animal, grade C]
- Laroui H, Dalmasso G, Nguyen HT et al. (2010). Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology. PubMed 19909746 · doi:10.1053/j.gastro.2009.11.003[Animal, grade C]
- Xiao B, Xu Z, Viennois E et al. (2017). Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Mol Ther. PubMed 28143741 · doi:10.1016/j.ymthe.2016.11.020[Animal, grade C]
- Cheng J, Wu P, Li C et al. (2026). Inflammation-triggered self-immolative conjugates enable oral peptide delivery by overcoming gastrointestinal barriers. Sci Adv. PubMed 41533788 · doi:10.1126/sciadv.aea2989[Animal, grade C]
- Gravina AG, Pellegrino R, Durante T et al. (2023). The Melanocortin System in Inflammatory Bowel Diseases: Insights into Its Mechanisms and Therapeutic Potentials. Cells. PubMed 37508552 · doi:10.3390/cells12141889[Review, grade R]
- U.S. Food and Drug Administration, Pharmacy Compounding Advisory Committee (2026-07-23). FDA Briefing Document: KPV-Related Bulk Drug Substances (KPV (free base) and KPV acetate). Source[retrieved 2026-11-11]